The coagulation cascade is the enzymatic amplification system of secondary hemostasis that generates a stable fibrin clot. While traditionally described as intrinsic, extrinsic, and common pathways, the contemporary cell-based model emphasizes that coagulation occurs on cell surfaces in overlapping phases: initiation, amplification, and propagation.
The Classic Cascade Model
The intrinsic pathway (contact activation pathway) begins when factor XII (Hageman factor) contacts negatively charged surfaces (kallikrein, high-molecular-weight kininogen). This activates factor XII to XIIa, which activates factor XI to XIa. Factor XIa activates factor IX to IXa, which with factor VIIIa forms the tenase complex on platelet surfaces, activating factor X. The extrinsic pathway (tissue factor pathway) is initiated when tissue factor (TF) from damaged endothelium binds and activates factor VII. The TF-VIIa complex directly activates factor X. The common pathway begins with factor Xa, which with factor Va forms the prothrombinase complex on platelet surfaces, converting prothrombin (factor II) to thrombin (factor IIa). Thrombin cleaves fibrinogen (factor I) to fibrin monomers that polymerize, and activates factor XIII, which cross-links fibrin polymers into a stable clot.
Coagulation Factors
Prothrombin (factor II) is a vitamin K-dependent zymogen synthesized in the liver. Tissue factor (factor III) is a transmembrane glycoprotein expressed on subendothelial cells and upregulated by inflammatory cytokines. Calcium (factor IV) is required for the assembly of tenase and prothrombinase complexes on phospholipid surfaces. Factor V is an essential cofactor in the prothrombinase complex; it is activated by thrombin and inactivated by activated protein C. Factor VII is a vitamin K-dependent zymogen; its activated form (VIIa) binds tissue factor to initiate coagulation. Factor VIII is cofactor for factor IXa in the tenase complex; its deficiency causes hemophilia A. Factor IX is a vitamin K-dependent zymogen; its deficiency causes hemophilia B (Christmas disease). Factor X is the convergence point of intrinsic and extrinsic pathways, forming the prothrombinase complex with factor Va. Factor XI is activated by factor XIIa and amplifies thrombin generation. Factor XIII cross-links fibrin polymers, stabilizing the clot against fibrinolysis.
The Cell-Based Model of Coagulation
The cell-based model describes three overlapping phases. In the initiation phase, tissue factor-bearing cells (fibroblasts, smooth muscle cells) bind factor VIIa, and the TF-VIIa complex activates small amounts of factors IX and X. Factor Xa generates trace thrombin, insufficient for fibrin formation but critical for amplification. In the amplification phase, trace thrombin activates platelets, platelets degranulate and expose phosphatidylserine on their surface, and thrombin activates factors V, VIII, and XI on platelet surfaces. In the propagation phase, activated platelets provide the surface for tenase (IXa-VIIIa) and prothrombinase (Xa-Va) complex assembly, generating a burst of thrombin — the thrombin burst — that rapidly converts fibrinogen to fibrin and activates factor XIII for clot stabilization.
Vitamin K-Dependent Factors
Factors II (prothrombin), VII, IX, and X, as well as proteins C and S, require vitamin K for their synthesis. Vitamin K is a cofactor for gamma-glutamyl carboxylase, which adds a carboxyl group to glutamic acid residues, creating gamma-carboxyglutamic acid (Gla) residues that enable calcium-dependent binding to phospholipid membranes. Warfarin (vitamin K antagonist) inhibits vitamin K epoxide reductase, blocking the recycling of vitamin K and producing undercarboxylated, non-functional factors. The PT (extrinsic pathway) is most sensitive to warfarin because factor VII has the shortest half-life (4–6 hours), making PT and INR the test of choice for warfarin monitoring.
Natural Anticoagulants
The cascade is balanced by endogenous anticoagulants. Antithrombin inactivates thrombin and factors Xa, IXa, XIa, and XIIa. The protein C pathway: thrombin binds thrombomodulin on intact endothelium, activating protein C (APC), which with protein S inactivates factors Va and VIIIa. Tissue factor pathway inhibitor (TFPI) directly inhibits the TF-VIIa-Xa complex. Deficiency of antithrombin, protein C, or protein S increases thrombosis risk. Activated protein C resistance (factor V Leiden mutation) is the most common inherited thrombophilia, caused by a point mutation (R506Q) that prevents APC cleavage of factor Va.
Laboratory Testing
The coagulation cascade is assessed by the PT (extrinsic pathway), aPTT (intrinsic pathway), and thrombin time (common pathway). Mixing studies distinguish factor deficiency from inhibitor. Specific factor assays (one-stage clotting assays based on PT or aPTT with factor-deficient plasma) quantify individual factor activity. Thrombin generation assays (calibrated automated thrombography) provide a global assessment of coagulation potential but remain primarily research tools.
